THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Monday, April 26, 2021
Albumedix’s ambitious growth plan focuses on empowering excellence for innovative therapy and next-generation biopharmaceutical entrepreneurs, allowing stable and scalable treatments to reach patients around the world.
FREMONT, CA: Albumedix, a recognized global leader in recombinant human albumin specializing in the enablement of advanced therapies, has completed the expansion of its commercial-scale manufacturing facility in Nottingham and the development of a new Technology Centre with state-of-the-art laboratories.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
“Biopharmaceuticals has for a long time been a truly innovative corner of our industry; over the past 5-10 years we have experienced the incredible speed by which cellular and gene therapies have moved from jaw-dropping science to transformative therapies”, Albumedix Chief Executive Officer Jonas SkjødtMøller comments and continues. “We are proud to play our part and remain committed to enable the global development of safe, stable and scalable therapies”.
Albumedix’s ambitious growth plan focuses on empowering excellence for innovative therapy and next-generation biopharmaceutical entrepreneurs, allowing stable and scalable treatments to reach patients around the world.The company is now officially manufacturing out of its latest four-story manufacturing expansion, which has greatly increased its annual product volume after more than three years of design and development. Stuart Woodward, Chief Manufacturing Officer, Albumedix, says, “The growth of our manufacturing capability here in Nottingham is a major achievement for our company and our Albumedix colleagues.”
Albumedix’s expanded manufacturing facility will meet the rising demand from a list of clients that use its goods and innovations in the production of cell therapies, gene therapies, vaccinations, medical equipment, diagnostics, and protein and peptide therapeutics.
“It has been an exciting journey from design, through ground-breaking and finally construction of a four-story building towering over the campus,” Stuart comments and continues reflecting on the finalization of the expansion. “Now fully operational, the number of batches coming through from our new and expanded facility are rapidly increasing and we are delighted to cement our commitment for secure supply of high-quality products to our valued customers and partners.”
Albumedix brings its more than 35 years of experience working with albumin in various applications and concentrating its people and expertise on one campus to serve its customers better.On the Albumedix campus, a brand-new Technology Centre has now been established, with facilities classified at BSL2 and BSL2+; Phil Morton explains: “This will allow us to enable more innovation and help drive a hand-held support for our customers in the advanced therapy field.”
In this newly established Centre, Albumedix’s team of dedicated scientists will continue to support customers and investigate the critical benefits albumin can offer advanced therapy and biopharmaceutical developers. “As a science driven company, upgrading our research facilities builds upon our customer-centric philosophy and capabilities to support our customers and partners through our in-house expertise in albumin and its applications,” Phil adds.
More in News